Covid-19 vaccine was cleared for use in Canada, creating a novel immunization to combat the virus from a unit of Mitsubishi Chemical Holdings Corp.
and Philip Morris International. The vaccine named Covifenz was jointly developed by Medicago Inc., a biopharma company owned by Mitsubishi Chemical and Philip Morris and based in Quebec City, and GlaxoSmithKline Plc.
It will be available for adults aged 18 to 64, Health Canada said in a statement Tuesday. The approval gives people who are hesitant to take currently available vaccines made by Pfizer Inc., AstraZeneca Plc and Moderna Inc.
another option. Many countries are struggling to raise vaccination rates and are requiring citizens to be immunized to get into restaurants, shopping malls trains and planes.